Report an error   
Submitted: 09 May 2017 Modified: 06 June 2017

Herdin Record #: PCHRD17050915385212

Rivastigmine: The advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.

Researchers

NameRole
1Stephen Christopher Author
2Ananda Krishna Karanam Author
3 Kyung Won Park Author
4Encarnita Ampil Author
5 Irene Looi Author
6Vorapun Senanarong Author
7Ming-Chyi Pai Author
8Nagaendran Kandiah Author

Publication Information

1.
Publication Type:
Journal
Title:
Clinical Interventions in Agin
Publication Date:
April 2018
Volume:
12
Page(s):
697–707.
Publisher:
Auckland : Dove Medical Press

Abstract

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique cholinesterase inhibitor with both AChE and butyrylcholinesterase (BuChE; EC 3.1.1.8) inhibitory activity. Rivastigmine is also available as transdermal patch that has been approved by the US Food and Drug Administration for the treatment of mild, moderate, and severe AD as well as mild-to-moderate PDD. In this review, we explore the role of BuChE inhibition in addition to AChE inhibition with rivastigmine in the outcomes of cognition, global function, behavioral symptoms, and activities of daily living. Additionally, we review the evidence supporting the use of dual AChE


Physical Location

LocationCall NumberAvailable FormatAvailability
U.S. National Library of Medicine: PubMed/Medline Fulltext External Link (View)